---
figid: PMC4527365__bmi-suppl.3-2015-001f2
figlink: /pmc/articles/PMC4527365/figure/f2-bmi-suppl.3-2015-001/
number: F2
caption: 'Activation and downstream signaling of class III RTKs. In the inactivated
  state, RTKs are auto-inhibited by the JMD (purple line) in cis. Ligand binding occurs
  in the ED indicated by orange, purple, green, and blue circles. Ligands of RTKs
  discussed in this review are specified in the upper left box and the ligand is depicted
  as a grey double-hexagon. Ligand binding induces the oligomerization of the receptor.
  Thereby, the IgG-like domains of the ED rotate to form an efficient receptor–ligand
  complex. This induces transphosphorylation of tyrosine residues in the TKD (purple
  circles) and JMD (purple line). Phosphorylation of the JMD leads to the release
  of the inhibitory conformation and to the swing out of the tyrosine side chains.
  The phosphate is generated through transformation of ATP to adenosine diphosphate.
  Thereby, the conformational change (into trans) of the RTK processes from a transactivated
  to a fully activated state. In the activated state, the titling angle of the ligand
  shifts when the ternary complex is generated with the exception of PDGF. In addition,
  the activation loop (red line) establishes an active conformation enabling the binding
  of substrates (turquoise hexagon) and ATP. Downstream signaling is achieved by phosphorylation
  (indicated as orange circles with P) of signaling molecules described in the right
  part of the figure. This includes PLCγ, JAK/STATs, PI3K, and the MAPK signaling
  pathway. These signaling pathways regulate the transcription of various genes implicated
  in cell proliferation, migration, survival, angiogenesis, and cell cycle progress.
  Constitutive activation of RTKs by different mutations would lead to constitutive
  phosphorylation of downstream effectors and deregulation of the transcription of
  genes implicated in cell proliferation and others. Adapted by permission from Macmillan
  Publishers Ltd, Nat. Rev Cancer. Verstraete K and Savvides SN. Extracellular assembly
  and activation principles of oncogenic class III receptor tyrosine kinases. Nat
  Rev Cancer. 2012;12(11):753–766. Copyright 2012.Abbreviatons: Grb2, growth factor
  receptor–bound protein 2; Sos, son of sevenless; Raf, rat fibrosarcoma; ERK, extracellular
  signal-regulated kinase; MEK, mitogen-activated protein kinase kinase.'
pmcid: PMC4527365
papertitle: Class III Receptor Tyrosine Kinases in Acute Leukemia – Biological Functions
  and Modern Laboratory Analysis.
reftext: Rimma Berenstein. Biomark Insights. 2015;10(Suppl 3):1-14.
pmc_ranked_result_index: '74942'
pathway_score: 0.7476767
filename: bmi-suppl.3-2015-001f2.jpg
figtitle: Activation and downstream signaling of class III RTKs
year: '2015'
organisms:
- Homo sapiens
ndex: 517af881-de98-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4527365__bmi-suppl.3-2015-001f2.html
  '@type': Dataset
  description: 'Activation and downstream signaling of class III RTKs. In the inactivated
    state, RTKs are auto-inhibited by the JMD (purple line) in cis. Ligand binding
    occurs in the ED indicated by orange, purple, green, and blue circles. Ligands
    of RTKs discussed in this review are specified in the upper left box and the ligand
    is depicted as a grey double-hexagon. Ligand binding induces the oligomerization
    of the receptor. Thereby, the IgG-like domains of the ED rotate to form an efficient
    receptor–ligand complex. This induces transphosphorylation of tyrosine residues
    in the TKD (purple circles) and JMD (purple line). Phosphorylation of the JMD
    leads to the release of the inhibitory conformation and to the swing out of the
    tyrosine side chains. The phosphate is generated through transformation of ATP
    to adenosine diphosphate. Thereby, the conformational change (into trans) of the
    RTK processes from a transactivated to a fully activated state. In the activated
    state, the titling angle of the ligand shifts when the ternary complex is generated
    with the exception of PDGF. In addition, the activation loop (red line) establishes
    an active conformation enabling the binding of substrates (turquoise hexagon)
    and ATP. Downstream signaling is achieved by phosphorylation (indicated as orange
    circles with P) of signaling molecules described in the right part of the figure.
    This includes PLCγ, JAK/STATs, PI3K, and the MAPK signaling pathway. These signaling
    pathways regulate the transcription of various genes implicated in cell proliferation,
    migration, survival, angiogenesis, and cell cycle progress. Constitutive activation
    of RTKs by different mutations would lead to constitutive phosphorylation of downstream
    effectors and deregulation of the transcription of genes implicated in cell proliferation
    and others. Adapted by permission from Macmillan Publishers Ltd, Nat. Rev Cancer.
    Verstraete K and Savvides SN. Extracellular assembly and activation principles
    of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer. 2012;12(11):753–766.
    Copyright 2012.Abbreviatons: Grb2, growth factor receptor–bound protein 2; Sos,
    son of sevenless; Raf, rat fibrosarcoma; ERK, extracellular signal-regulated kinase;
    MEK, mitogen-activated protein kinase kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF1
  - HRAS
  - NRAS
  - AKT3
  - PDGFB
  - PDGFD
  - PDGFC
  - KRAS
  - PIK3CB
  - PIK3CD
  - PDGFA
  - MAP2K1
  - PLCG2
  - ARAF
  - MAPK3
  - KIT
  - CSF1R
  - KITLG
  - BRAF
  - PIK3R4
  - PIK3CA
  - JAK2
  - TYK2
  - PIK3R3
  - AKT1
  - PLCG1
  - FLT3
  - AKT2
  - PRKD3
  - PIK3R5
  - GRB2
  - SOS1
  - SOS2
  - PRKCZ
  - PRKCI
  - MAP2K2
  - MAPK1
  - PIK3R6
  - PDGFRA
  - PDGFRB
  - WDTC1
  - PRKCQ
  - PRKCH
  - PRKCG
  - PIK3CG
  - PRKCB
  - PRKCD
  - JAK1
  - JAK3
  - PRKCA
  - PRKCE
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PKB/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: c-Kit
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: CSF1R
  symbol: CSF1R
  source: hgnc_symbol
  hgnc_symbol: CSF1R
  entrez: '1436'
- word: SCF
  symbol: SCF
  source: hgnc_alias_symbol
  hgnc_symbol: KITLG
  entrez: '4254'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PKB/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: FLT3
  symbol: FLT3
  source: hgnc_symbol
  hgnc_symbol: FLT3
  entrez: '2322'
- word: PKB/Akt
  symbol: PKB
  source: hgnc_alias_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PKB/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: ADP
  symbol: ADP
  source: hgnc_alias_symbol
  hgnc_symbol: WDTC1
  entrez: '23038'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4527365__F2
redirect_from: /figures/PMC4527365__F2
figtype: Figure
---
